-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Royal Bank of Canada
Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by Royal Bank of Canada
Analysts at Royal Bank of Canada initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) in a report issued on Friday, The Fly reports. The firm set an "outperform" rating and a $23.00 price target on the biopharmaceutical company's stock. Royal Bank of Canada's price objective would suggest a potential upside of 307.08% from the stock's previous close.
MRNS has been the topic of several other research reports. StockNews.com raised Marinus Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, November 14th. Robert W. Baird dropped their target price on Marinus Pharmaceuticals from $32.00 to $24.00 and set an "outperform" rating on the stock in a report on Wednesday, November 9th. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 target price on shares of Marinus Pharmaceuticals in a report on Friday, January 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $28.63.
Get Marinus Pharmaceuticals alerts:Marinus Pharmaceuticals Stock Performance
Shares of NASDAQ MRNS opened at $5.65 on Friday. The company has a current ratio of 8.41, a quick ratio of 8.40 and a debt-to-equity ratio of 0.91. The stock has a 50 day simple moving average of $4.41 and a 200-day simple moving average of $5.46. The company has a market cap of $210.16 million, a PE ratio of -12.28 and a beta of 1.10. Marinus Pharmaceuticals has a 12-month low of $3.46 and a 12-month high of $12.37.
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) last issued its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.60). The business had revenue of $2.34 million for the quarter, compared to analyst estimates of $28.56 million. Marinus Pharmaceuticals had a negative return on equity of 244.60% and a negative net margin of 77.96%. On average, equities research analysts forecast that Marinus Pharmaceuticals will post -2.74 EPS for the current year.Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of MRNS. Quantbot Technologies LP bought a new position in shares of Marinus Pharmaceuticals in the first quarter valued at $40,000. Amalgamated Bank purchased a new position in Marinus Pharmaceuticals during the 1st quarter worth approximately $56,000. PDT Partners LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $63,000. Laurion Capital Management LP purchased a new position in Marinus Pharmaceuticals during the 2nd quarter worth approximately $74,000. Finally, Price T Rowe Associates Inc. MD grew its position in Marinus Pharmaceuticals by 39.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 15,600 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 4,417 shares in the last quarter. Institutional investors own 86.88% of the company's stock.
About Marinus Pharmaceuticals
(Get Rating)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
See Also
- Get a free copy of the StockNews.com research report on Marinus Pharmaceuticals (MRNS)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
加拿大皇家银行的分析师发起了对马里纳斯制药(纳斯达克:MRNS-GET评级)在周五发布的一份报告中,苍蝇报告说。该公司为这家生物制药公司的股票设定了“跑赢大盘”的评级和23.00美元的目标价。加拿大皇家银行的目标股价暗示,该股较前一交易日收盘价有307.08%的潜在上涨空间。
MRNS一直是其他几份研究报告的主题。在11月14日周一的一份报告中,StockNews.com将Marinus PharmPharmticals的评级从“卖出”上调至“持有”。罗伯特·W·贝尔德在11月9日星期三的一份报告中将Marinus PharmPharmticals的目标价从32.00美元下调至24.00美元,并对该股设定了“跑赢大盘”的评级。最后,在1月6日星期五的一份报告中,HC Wainwright重新发布了“买入”评级,并为Marinus制药公司的股票设定了27美元的目标价。一位研究分析师对该股的评级为持有,七位分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该股目前的平均评级为“中等买入”,平均目标价为28.63美元。
到达Marinus制药公司警报:Marinus制药公司股票表现
上周五,纳斯达克MRNS的股价开盘报5.65美元。该公司的流动比率为8.41,速动比率为8.40,债务权益比率为0.91。该股的50日简单移动均线切入位为4.41美元,200日简单移动均线切入位为5.46美元。该公司市值为2.1016亿美元,市盈率为-12.28,贝塔系数为1.10。Marinus PharmPharmticals的12个月低点为3.46美元,12个月高位为12.37美元。
马瑞纳斯制药公司(纳斯达克代码:MRNS-GET Rating)最近一次发布季度收益数据是在11月7日星期一。这家生物制药公司公布了本季度每股收益(EPS)(0.35美元),低于普遍预期的0.25美元(0.60美元)。该业务本季度营收为234万美元,而分析师预期为2856万美元。Marinus制药公司的净资产回报率为负244.60%,净利润率为负77.96%。股票研究分析师平均预测,Marinus PharmPharmticals本年度每股收益将达到2.74欧元。机构资金流入和流出
几家机构投资者最近调整了对MRN的持有量。Quantbot Technologies LP在第一季度购买了Marinus PharmPharmticals的新头寸,价值4万美元。合并银行在第一季度购买了Marinus制药公司的一个新头寸,价值约5.6万美元。PDT Partners LLC在第二季度购买了Marinus制药公司的一个新头寸,价值约6.3万美元。Laurion Capital Management LP在第二季度购买了Marinus制药公司的一个新头寸,价值约7.4万美元。最后,Price T Rowe Associates Inc.MD在第二季度将其在Marinus制药公司的头寸增加了39.5%。Price T Rowe Associates Inc.MD现在拥有15,600股这家生物制药公司的股票,价值76,000美元,此前在上个季度又购买了4,417股。机构投资者持有该公司86.88%的股票。
关于Marinus制药公司
(获取评级)
Marinus制药公司是一家制药公司,专注于为患有罕见遗传性癫痫和其他癫痫障碍的患者开发和商业化产品。它提供ZTALMY,一种口服混悬剂,用于治疗与急性和慢性护理中的成人和儿童患者群体以及住院和自我给药环境中的细胞周期蛋白依赖性激酶样缺乏症相关的癫痫发作。
另请参阅
- 免费获取StockNews.com关于Marinus制药的研究报告(MRNS)
- 市场回顾周-1/16-1/20
- Old Dominion是否表明Trucking正在踩刹车?
- 诺德斯特龙对零售业降价的担忧
- 埃克森美孚股票:在Buy Point附近
- 高股息率的必和必拓认为中国推动了23年的增长
获得Marinus PharmPharmticals Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Marinus制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧